# Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

> **NCT00520780** · PHASE3 · COMPLETED · sponsor: **Vifor Pharma** · enrollment: 456 (actual)

## Conditions studied

- Chronic Heart Failure
- Iron Deficiency
- Iron Deficiency Anemia
- Anaemia

## Interventions

- **DRUG:** Ferinject ® (Ferric carboxymaltose)
- **DRUG:** Normal saline (0.9%)

## Key facts

- **NCT ID:** NCT00520780
- **Lead sponsor:** Vifor Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-07
- **Final completion:** 2009-09
- **Target enrollment:** 456 (ACTUAL)
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520780, "Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00520780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*